Number of Applicants
:000+
Let AI Supercharge Your Job Hunt!
JobCopilot scans 500,000+ company career sites daily to find jobs for you
Principal Project Manager
Chesterford Research Park – Cambridge
Full Time Permanent
Hybrid and on-site working
On Site Parking
Full benefits package
Never losing sight of our purpose
Mestag Therapeutics is a clinical-stage biotechnology company pioneering the discovery and development of antibody therapeutics targeting cancer and inflammatory disease. Our science is rooted in fibroblast immunology, leveraging cutting-edge biological and translational insights to uncover novel pathways that drive immune modulation in disease.
Mestag is backed by committed leading global investors, has world-class founders and a highly experienced leadership team.
We are now transitioning our lead programme into clinic - there has never been a better time to join #TeamMestag
Scope of role
The Principal Project Manager will report into the Chief Development Officer as a member of the project management team, working closely with senior function leads across the organisation. You will provide project management support to target discovery activities, new/early antibody therapeutic programs, and to selected business development activities. Your role will include managing budgets, preparing and driving timelines and scenarios, organising meetings, supporting Program Leads in facilitating program-level decision-making, internal and external stakeholder management and active support to critical company decision-making.
You will play a central role as:
Key Responsibilities
Target Discovery & RAFT Platform
Programme Planning
Programme Operations
Programme Information/Communication
New / Early Programs
Member of Project management team
Minimum Qualifications and Experience Required.
Project Management:
Other Experience/Abilities:
In return we can offer you
You will join our expert project management team and help shape Mestag's target discovery and highly specialist RAFT platform internally and via collaboration with leading pharma companies. You will also play a key role in shaping our early and future therapeutic portfolio. Now is an exciting time to join our company as we progress our lead bispecific into clinical trial.
We work flexibly with a strong team spirit and offer a highly competitive total rewards package including competitive salaries, pension contributions, private medical insurance, income protection and more. We have access to a range of onsite facilities including a gym, canteen, golf course and free on-site parking.
As a team we achieve great things each day, and we take the time to celebrate successes, share and learn. We value the relationships of our close-knit team and strive to make meaningful connections in our community. We frequently hold Town Halls and team lunches, and have an active social committee, organizing regular events and ‘giving back’ activities supporting charities close to our hearts.
Feel free to have an informal discussion with us for any questions you may have, we are happy to talk to you.
About Mestag Therapeutics
Mestag harnesses new insights into fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases. We are progressing a unique pipeline of novel antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology.
Our pipeline includes MST-0312, a FAP-targeted LTBR agonist bispecific antibody that leverages a new understanding of tertiary lymphoid structures (TLSs) in solid tumors and their role in driving improved patient outcomes; the M402 program, an agonist antibody targeting a stromal inhibitory receptor to dampen down the activation of specific immune cell subsets in inflammatory disease; and earlier programs in discovery stage.
Separately, we are also identifying novel targets for future therapies utilizing our specialist fibroblast-immune RAFT Platform. In 2024, we entered into a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for inflammatory diseases, and licensed a novel target to Johnson & Johnson under a 2021 target discovery, option and license agreement with Janssen Biotech, Inc.
Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. Mestag was founded by SV Health Investors and is supported by leading life science investors Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (Google Ventures) and Northpond Ventures.
For further information, please visit our website www.mestagtherapeutics.com.
Auto-Apply to Principal Project Manager Jobs with your AI JobCopilot
Copyright © 2026 Grabjobs Pte.Ltd. All Rights Reserved.